CRDF

Conviction 0HealthcareScan · Thu, Jun 25, 2026

CRDF$1.21-3.97%

ResistanceSupportVol 14Insider buy

Vol MA14 1.3M

Mar 26Apr 14May 1May 19Jun 8Jun 25

Cardiff Oncology, Inc.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.cardiffoncology.com ↗

Price1.21

Change-3.97%

Gap+5.56%

Rel volume0.90×

Avg volume1.63M

Avg $ vol2.36M

SMA 201.45

SMA 501.61

SMA 2002.01

Price vs 50-24.62%

Price vs 200-39.72%

MA stackbearish

50/200 cross—

Supertrenddown · 1.70

RSI (14)37

MACD hist-0.02

MACD cross—

Stoch %K / %D11 / 17

ADX (14)23

+DI / −DI16 / 27

RSI divergence—

MACD divergence—

ATR %+11.74%

ADR %10.36%

52w high4.45

52w low1.18

From 52w high-72.81%

Above 52w low+2.54%

New 52w highNo

SqueezeOff

Bollinger width53.04%

%B0.19

Donchian pos6.67%

Donchian high1.91

Donchian low1.16

AVWAP (52w high)2.22

vs AVWAP high-45.53%

AVWAP (52w low)1.26

vs AVWAP low-3.92%

OBV trendDown

Chaikin MF (20)-0.37

Today vs 20d0.90×

Avg vol (14d)1.3M

Avg vol (20d)1.63M

Avg $ vol (20d)2.36M

Market cap82.73M

RS 3m (vs SPY)-39.42%

RS 6m (vs SPY)-58.71%

RS line new highNo

Trend template0/8

Technical rank6.1

1 week+2.54%

1 month-37.63%

3 months-30.06%

6 months-58.56%

1 year-62.19%

YTD-54.51%

P/E-1.80

P/B2.38

P/S139.51

P/FCF-2.18

EPS-0.6900

Div yield—

ROE-132.10%

ROA-93.25%

Debt/Eq—

Current3.27

EV/EBITDA-1.53

Gross margin—

Net margin—

Rev growth-13.18%

EPS growth-0.92%

Price target—

Target upside—

Analyst rating—

Institutional—

Ent. value74.18M

Revenue41K

Net income-12.35M

Gross profit—

Free cash flow-37.97M

IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

ExchangeNasdaq

Shares out68.37M

Employees31

ListedThu, May 22, 1997

Free float64.31M

Float %94.1%

Short interest18.13M

Days to cover12.3d

Short volume33.5%

Squeeze score65 / 100

Next earningsTue, Aug 4, 2026 (40d)

EPS forecast−$0.17 · 5 est

Last EPS vs est—

Last surprise—

Setup gradeD

Conviction0 / 100

Pattern quality—

Tech rank6.1 / 100

Group rank50 / 100

Status laneNo active setup

Setup direction—

Pattern family

Resistance2.00

Support1.26

Days since event—

Candle confirm—

News sentiment—

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in CRDF

All disclosures →

No recent disclosed trades by Congress in CRDF. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in CRDF · 6 buys

Insider	Side	Shares	Value	Traded	Filed
Mohindru Mani Chief Executive Officer · Common Stock · 2026-06-18	Buy	24.7K	$30K	2026-06-18	2026-06-22
PACE GARY W Director · Common Stock · 2026-06-18	Buy	30K	$37K	2026-06-18	2026-06-22
Aggarwal Ajay Chief Operating Officer · Stock Options · 2026-04-27	Grant	400K	$0	2026-04-27	2026-04-28
Smeal Tod Chief Scientific Officer · Stock Options · 2026-04-14	Grant	300K	$0	2026-04-14	2026-04-16
Muntner Joshua B Chief Financial Officer · Common Stock · 2026-04-06	Other	—	—	2026-04-06	2026-04-16
Muntner Joshua B Chief Financial Officer · Stock Options · 2026-04-06	Grant	486.65K	$0	2026-04-06	2026-04-16
Muntner Joshua B Chief Financial Officer · Stock Options · 2026-04-06	Grant	486.65K	$0	2026-04-06	2026-04-16

SEC filings

EDGAR filings in CRDF · 2 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.

Start free — 7-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.